Maharashtra FDA Revokes Cipla's Pune Drug Licenses Due to Violations
Cipla's drug distribution licenses in Pune have been cancelled by the Maharashtra FDA over significant regulatory breaches.
The Maharashtra FDA has cancelled Cipla's drug sale and distribution licenses effective October 1, 2026.
Regulatory violations include misbranding of Reactin Plus Tablets and packaging discrepancies.
Cipla's recent financial report shows a 39.2% year-on-year decline in net profit for Q1 FY27.
The Maharashtra Food and Drug Administration (FDA) has taken decisive action by cancelling the drug sale and distribution licenses of Cipla's facility located in Wadki, Pune, effective from October 1, 2026. This decision was prompted by serious violations related to the packaging and storage of Reactin Plus Tablets, a prescription medication. Cipla has publicly expressed its disappointment regarding the ruling and is currently assessing the regulatory order.
This regulatory action follows a series of inspections that revealed significant lapses in compliance with the Drugs and Cosmetics Act, 1940. The FDA's findings indicated that the packaging for Reactin Plus Tablets included unauthorized therapeutic claims, which constitutes a breach of established regulations. The cancellation order was issued by the Assistant Commissioner (Drugs) after a thorough review and personal hearings, addressing previous criticisms from the Bombay High Court regarding procedural fairness in earlier rulings.
In terms of financial implications, Cipla reported a consolidated net profit of ₹789.05 crore for the first quarter of FY27, marking a notable 39.2% decrease compared to ₹1,297.62 crore in the same quarter the previous year. However, there was a sequential recovery of 42.3% from the previous quarter, indicating potential resilience despite the regulatory challenges. The company's revenue from product sales also saw a modest year-on-year growth of 3.5%, totaling ₹7,077.02 crore.
The cancellation of the licenses is expected to have limited impact on Cipla's overall operations, as the company can reroute supplies through other distribution centers. Nevertheless, localized supply chains in western India may face temporary disruptions. The broader pharmaceutical industry may need to adjust to heightened compliance scrutiny from state regulators, which could influence operational strategies moving forward.
Looking ahead, Cipla may pursue legal avenues to contest the FDA's decision, which could lead to further developments in the coming months. The company is also focused on its strategic partnerships in oncology and biosimilars, which are crucial for its future growth. As the regulatory landscape continues to evolve, Cipla's ability to navigate these challenges will be vital for maintaining its market position.
